10-K: Allogene Therapeutics Focuses on Key Programs, Reports $257.6 Million Net Loss in 2024

Allogene Therapeutics prioritizes its LBCL, autoimmune disease, and RCC programs while reporting a $257.6 million net loss for the year ended December 31, 2024.

Summary

• Allogene Therapeutics is concentrating on three core programs: LBCL, autoimmune disease, and RCC.
• The company reported a net loss of $257.6 million for the year ended December 31, 2024, and had an accumulated deficit of $1.8 billion as of the same date.
• As of December 31, 2024, Allogene had $373.1 million in cash, cash equivalents, and investments, expected to fund operations into the second half of 2026.
• A pivotal Phase 2 clinical trial (ALPHA3) for cema-cel in LBCL was initiated in June 2024, with an interim analysis anticipated around mid-2025.
• Enrollment is complete in the Phase 1b TRAVERSE trial of ALLO-316 for advanced or metastatic RCC, with additional data expected in mid-2025.
• A Phase 1 clinical trial (RESOLUTION trial) of ALLO-329 for autoimmune diseases is planned for mid-2025, with initial proof-of-concept data anticipated around year-end 2025.
• The company is developing ALLO-647 as part of the lymphodepletion regimen for its oncology programs.
• Allogene is exploring opportunities to partner with collaborators on other product candidates across its pipeline.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While there are positive developments in the clinical trials and regulatory designations, the company is still incurring significant losses and faces numerous risks and uncertainties.

Positives

• ALLO-316 received Regenerative Medicine Advanced Therapy (RMAT) designation for adult patients with advanced or metastatic RCC.
• The FDA cleared the IND for ALLO-329, with a Phase 1 clinical trial (RESOLUTION trial) planned for mid-2025.
• The company is expanding its allogeneic CAR T platform into autoimmune disease treatment with ALLO-329, targeting both CD19 and CD70.
• The ALPHA3 trial leverages an investigational diagnostic test developed by Foresight Diagnostics to identify patients who have MRD at the completion of 1L chemoimmunotherapy.

Negatives

• Allogene Therapeutics reported a net loss of $257.6 million for the year ended December 31, 2024, and had an accumulated deficit of $1.8 billion as of the same date.
• The company is still in the clinical stage and has not generated any revenue from product sales to date.
• The company is reliant on Foresight Diagnostics to perform MRD testing for the ALPHA3 trial, and a delay or failure by Foresight Diagnostics to perform MRD testing may negatively impact the trial.
• The company is transferring ALLO-647 manufacturing to a new site, which will be time consuming, costly, and subject to uncertainty.

Risks

• The company's product candidates are based on novel technologies, which makes it difficult to predict the time and cost of product candidate development and the likelihood of obtaining regulatory approval.
• The company's business is highly dependent on the success of its lead product candidates.
• The company's product candidates may cause undesirable side effects or have other properties that have halted and could in the future halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.
• The company's clinical trials may fail to demonstrate the safety and efficacy of any of its product candidates, which would prevent or delay regulatory approval and commercialization.
• The company may encounter substantial delays in its clinical trials, or may not be able to conduct its trials on the timelines it expects.
• The company may fail to successfully manufacture its product candidates, operate its own manufacturing facility, or obtain regulatory approval to utilize or commercialize from its manufacturing facility or at a CDMO, which could adversely affect its clinical trials and the commercial viability of its product candidates.
• The company faces significant competition from other biotechnology and pharmaceutical companies, and its operating results will suffer if it fails to compete effectively.
• The company is highly dependent on its key personnel, and if it is not successful in attracting and retaining highly qualified personnel, it may not be able to successfully implement its business strategy.
• Changes in funding for the FDA, the SEC and other government agencies including comparable foreign regulatory authorities could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of the company's business may rely, which could negatively impact the company's business.

Future Outlook

Allogene expects its current cash, cash equivalents, and investments to fund operations into the second half of 2026. The company plans to continue research and development of its product candidates and seek regulatory approvals.

Management Comments

• Allogene executed its 2024 Platform Vision, which it believes will redefine the future of CAR T therapy by leveraging the unique attributes of allogeneic CAR T products.

Industry Context

The announcement highlights Allogene's efforts to compete in the rapidly evolving immuno-oncology market, particularly in CAR T cell therapy, where both autologous and allogeneic approaches are being developed. The company's focus on allogeneic therapies aims to address limitations of autologous therapies, such as lengthy delivery times and manufacturing challenges.

Comparison to Industry Standards

• Autologous CAR T therapies like Novartis' Kymriah and Gilead's Yescarta have achieved commercial success in treating certain blood cancers, but face challenges in manufacturing and accessibility.
• Allogeneic CAR T therapies, while promising, have yet to receive FDA approval, with companies like Atara Biotherapeutics and CRISPR Therapeutics also developing candidates.
• The company's ALPHA3 trial seeks to position cema-cel as a first-line consolidation therapy, a novel approach compared to existing CAR T therapies primarily used in later lines of treatment.
• The company is developing a diagnostic and treatment algorithm similar to what its management team previously helped develop for CRS and ICANS associated with autologous CAR T.

Stakeholder Impact

• Shareholders: The company's financial performance and progress in clinical trials will impact shareholder value.
• Employees: The company's workforce is key to its success, and the company is focused on culture, fairness, and retention.
• Patients: The company's product candidates have the potential to provide new treatment options for cancer and autoimmune diseases.
• Collaborators: The company relies on collaborations with third parties for various aspects of its business, including research, development, and manufacturing.

Next Steps

• Continue enrollment in the ALPHA3 trial, with an interim analysis anticipated around mid-2025.
• Announce additional data from the Phase 1b expansion cohort of the TRAVERSE trial in mid-2025.
• Initiate the Phase 1 clinical trial (RESOLUTION trial) of ALLO-329 in mid-2025.
• Seek scientific advice from European and UK regulatory authorities to assist with finalizing the regulatory strategy for the EU and the UK.

Key Dates

Keywords

Allogene Therapeutics, allogeneic CAR T, clinical trials, LBCL, autoimmune disease, RCC, cemacabtagene ansegedleucel, ALLO-316, ALLO-329, ALLO-647, FDA, RMAT designation, net loss, financial results, biopharmaceutical